Literature DB >> 31913560

Prevalence and management of diabetic neuropathy in secondary care in Qatar.

Georgios Ponirakis1,2, Tarik Elhadd3,4, Subitha Chinnaiyan3, Zeinab Dabbous3, Mashhood Siddiqui3, Hamad Al-Muhannadi1, Ioannis N Petropoulos1, Adnan Khan1, Khaled A E Ashawesh4, Khaled M O Dukhan4, Ziyad R Mahfoud1, Christopher Murgatroyd2, Mark Slevin2, Rayaz A Malik1,2,3,5.   

Abstract

AIMS: Diabetic neuropathy (DN) is a "Cinderella" complication, particularly in the Middle East. A high prevalence of undiagnosed DN and those at risk of diabetic foot ulceration (DFU) is a major concern. We have determined the prevalence of DN and its risk factors, DFU, and those at risk of DFU in patients with type 2 diabetes mellitus (T2DM) in secondary care in Qatar.
MATERIALS AND METHODS: Adults with T2DM were randomly selected from the two National Diabetes Centers in Qatar. DN was defined by the presence of neuropathic symptoms and a vibration perception threshold (VPT) ≥ 15 V. Participants with a VPT ≥ 25 V were categorized as high risk for DFU. Painful DN was defined by a DN4 score ≥4. Logistic regression analysis was used to identify predictors of DN.
RESULTS: In 1082 adults with T2DM (age 54 ± 11 years, duration of diabetes 10.0 ± 7.7 years, 60.6% males), the prevalence of DN was 23.0% (95% CI, 20.5%-25.5%) of whom 33.7% (95% CI, 27.9%-39.6%) were at high risk of DFU, and 6.3% had DFU; 82.0% of the patients with DN were previously undiagnosed. The prevalence of DN increased with age and duration of diabetes and was associated with poor glycaemic control (HbA1c  ≥ 9%) AOR = 2.1 (95% CI, 1.3-3.2), hyperlipidaemia AOR = 2.7 (95% CI, 1.5-5.0), and hypertension AOR = 2.0 (95% CI, 1.2-3.4).
CONCLUSIONS: Despite DN affecting 23% of adults with T2DM, 82% had not been previously diagnosed with one-third at high risk for DFU. This argues for annual screening and identification of patients with DN. Furthermore, we identify hyperglycaemia, hyperlipidaemia, and hypertension as predictors of DN.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  diabetic neuropathy; painful diabetic neuropathy, diabetic foot ulceration; type 2 diabetes mellitus

Mesh:

Year:  2020        PMID: 31913560     DOI: 10.1002/dmrr.3286

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  13 in total

Review 1.  Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.

Authors:  Gordon Sloan; Dinesh Selvarajah; Solomon Tesfaye
Journal:  Nat Rev Endocrinol       Date:  2021-05-28       Impact factor: 43.330

2.  An in vivo model for overloading-induced soft tissue injury.

Authors:  Panagiotis E Chatzistergos; Nachiappan Chockalingam
Journal:  Sci Rep       Date:  2022-04-11       Impact factor: 4.379

3.  Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection.

Authors:  Ariel Odriozola; Lucía Ortega; Lidia Martinez; Samantha Odriozola; Ainhoa Torrens; David Corroleu; Silvia Martínez; Meritxell Ponce; Yolanda Meije; Mercedes Presas; Alejandra Duarte; M Belén Odriozola; Rayaz A Malik
Journal:  Diabetes Res Clin Pract       Date:  2020-12-17       Impact factor: 8.180

Review 4.  Early Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres.

Authors:  Jamie Burgess; Bernhard Frank; Andrew Marshall; Rashaad S Khalil; Georgios Ponirakis; Ioannis N Petropoulos; Daniel J Cuthbertson; Rayaz A Malik; Uazman Alam
Journal:  Diagnostics (Basel)       Date:  2021-01-24

5.  Insulin Treatment Attenuates Small Nerve Fiber Damage in Rat Model of Type 2 Diabetes.

Authors:  Laura J Andreasen; Rikke K Kirk; Christian Fledelius; Mark A Yorek; Jens Lykkesfeldt; Thorbjorn Akerstrom
Journal:  J Diabetes Res       Date:  2020-08-02       Impact factor: 4.011

6.  Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT follow-up study).

Authors:  Dan Ziegler; Rüdiger Landgraf; Ralf Lobmann; Karlheinz Reiners; Kristian Rett; Oliver Schnell; Alexander Strom
Journal:  J Diabetes Investig       Date:  2020-05-09       Impact factor: 4.232

7.  Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.

Authors:  Georgios Ponirakis; Muhammad A Abdul-Ghani; Amin Jayyousi; Mahmoud A Zirie; Murtaza Qazi; Hamad Almuhannadi; Ioannis N Petropoulos; Adnan Khan; Hoda Gad; Osama Migahid; Ayman Megahed; Salma Al-Mohannadi; Fatema AlMarri; Fatima Al-Khayat; Ziyad Mahfoud; Hanadi Al Hamad; Marwan Ramadan; Ralph DeFronzo; Rayaz A Malik
Journal:  J Diabetes Investig       Date:  2021-05-03       Impact factor: 4.232

8.  Quantitative vibration perception threshold in assessing diabetic polyneuropathy: Should the cut-off value be adjusted for Chinese individuals with type 2 diabetes?

Authors:  Min Liu; Yun Gao; Da-Wei Chen; Shuang Lin; Chun Wang; Li-Hong Chen; Xing-Wu Ran
Journal:  J Diabetes Investig       Date:  2021-02-20       Impact factor: 4.232

9.  Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.

Authors:  Georgios Ponirakis; Muhammad A Abdul-Ghani; Amin Jayyousi; Mahmoud A Zirie; Salma Al-Mohannadi; Hamad Almuhannadi; Ioannis N Petropoulos; Adnan Khan; Hoda Gad; Osama Migahid; Ayman Megahed; Murtaza Qazi; Fatema AlMarri; Fatima Al-Khayat; Ziyad Mahfoud; Ralph DeFronzo; Rayaz A Malik
Journal:  J Diabetes Investig       Date:  2021-06-19       Impact factor: 4.232

10.  Prevalence and risk factors for diabetic neuropathy and painful diabetic neuropathy in primary and secondary healthcare in Qatar.

Authors:  Georgios Ponirakis; Tarik Elhadd; Subitha Chinnaiyan; Abdul H Hamza; Sanaulla Sheik; Mohamed A Kalathingal; Mohamed S Anodiyil; Zeinab Dabbous; Mashhood A Siddique; Hamad Almuhannadi; Ioannis N Petropoulos; Adnan Khan; Khaled Ae Ashawesh; Khaled M Dukhan; Ziyad R Mahfoud; Mahmoud A Zirie; Amin Jayyousi; Christopher Murgatroyd; Mark Slevin; Rayaz A Malik
Journal:  J Diabetes Investig       Date:  2020-09-14       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.